86
Participants
Start Date
August 8, 2022
Primary Completion Date
December 11, 2022
Study Completion Date
December 11, 2022
SHEN26 capsule
"Specification: 50mg/capsule and 200mg/capsule. Participants will receive SHEN26 capsule(s) orally for a single dose.~The specification of 50mg/capsule will only be used for the 50mg dose group in the SAD part. For the other dose groups and other parts of the study, 200mg/capsule will be used."
SHEN26 capsule
Specification: 200mg/capsule. Participants will receive SHEN26 capsules orally for Q12h X 5.5 days.
SHEN26 placebo
"Placebo matching the SHEN26 capsule. Specification: 50mg/capsule and 200mg/capsule.~Participants will receive SHEN26 placebo orally for a single dose."
SHEN26 placebo
"Placebo matching the SHEN26 capsule. Specification: 200mg/capsule.~Participants will receive SHEN26 placebo orally for Q12h X 5.5 days."
The Second Hospital of Anhui Medical University, Hefei
Shenzhen Kexing Pharmaceutical Co., Ltd.
NETWORK